Alnylam Pharmace. buy Maxi_Scalibusa
Start price
20.01.18
/
50%
€113.72
Target price
16.08.18
€336.00
Performance (%)
-27.30%
End price
16.08.18
€82.67
Summary
This prediction ended on 16.08.18 with a price of €82.67. The price of Alnylam Pharmace. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -27.30%. Maxi_Scalibusa has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -0.275% | -0.275% | -4.051% | 43.488% |
| iShares Core DAX® | -2.195% | 0.670% | 0.546% | 51.111% |
| iShares Nasdaq 100 | -2.629% | 2.992% | 34.108% | 91.988% |
| iShares Nikkei 225® | -2.021% | 3.141% | 53.424% | 65.852% |
| iShares S&P 500 | -1.670% | 2.405% | 23.220% | 66.636% |
Comments by Maxi_Scalibusa for this prediction
In the thread Alnylam Pharmace. diskutieren
(Vom Mitglied beendet)